BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38003662)

  • 1. Dependency of B-Cell Acute Lymphoblastic Leukemia and Multiple Myeloma Cell Lines on MEN1 Extends beyond MEN1-KMT2A Interaction.
    Wolffhardt TM; Ketzer F; Telese S; Wirth T; Ushmorov A
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML.
    Bourgeois W; Cutler JA; Aubrey BJ; Wenge DV; Perner F; Martucci C; Henrich JA; Klega K; Nowak RP; Donovan KA; Boileau M; Wen Y; Hatton C; Apazidis AA; Olsen SN; Kirmani N; Pikman Y; Pollard JA; Perry JA; Sperling AS; Ebert BL; McGeehan GM; Crompton BD; Fischer ES; Armstrong SA
    Blood; 2024 Apr; 143(15):1513-1527. PubMed ID: 38096371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia.
    Geng H; Brennan S; Milne TA; Chen WY; Li Y; Hurtz C; Kweon SM; Zickl L; Shojaee S; Neuberg D; Huang C; Biswas D; Xin Y; Racevskis J; Ketterling RP; Luger SM; Lazarus H; Tallman MS; Rowe JM; Litzow MR; Guzman ML; Allis CD; Roeder RG; Müschen M; Paietta E; Elemento O; Melnick AM
    Cancer Discov; 2012 Nov; 2(11):1004-23. PubMed ID: 23107779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute leukemias harboring KMT2A/MLLT10 fusion: a 10-year experience from a single genomics laboratory.
    Peterson JF; Sukov WR; Pitel BA; Smoley SA; Pearce KE; Meyer RG; Williamson CM; Smadbeck JB; Vasmatzis G; Hoppman NL; Greipp PT; Baughn LB; Ketterling RP
    Genes Chromosomes Cancer; 2019 Aug; 58(8):567-577. PubMed ID: 30707474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia.
    Krivtsov AV; Evans K; Gadrey JY; Eschle BK; Hatton C; Uckelmann HJ; Ross KN; Perner F; Olsen SN; Pritchard T; McDermott L; Jones CD; Jing D; Braytee A; Chacon D; Earley E; McKeever BM; Claremon D; Gifford AJ; Lee HJ; Teicher BA; Pimanda JE; Beck D; Perry JA; Smith MA; McGeehan GM; Lock RB; Armstrong SA
    Cancer Cell; 2019 Dec; 36(6):660-673.e11. PubMed ID: 31821784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrative methylome-transcriptome analysis unravels cancer cell vulnerabilities in infant MLL-rearranged B cell acute lymphoblastic leukemia.
    Tejedor JR; Bueno C; Vinyoles M; Petazzi P; Agraz-Doblas A; Cobo I; Torres-Ruiz R; Bayón GF; Pérez RF; López-Tamargo S; Gutierrez-Agüera F; Santamarina-Ojeda P; Ramírez-Orellana M; Bardini M; Cazzaniga G; Ballerini P; Schneider P; Stam RW; Varela I; Fraga MF; Fernández AF; Menéndez P
    J Clin Invest; 2021 Jul; 131(13):. PubMed ID: 33983906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First report of t(5;11) KMT2A-MAML1 fusion in de novo infant acute lymphoblastic leukemia.
    Tandon S; Shago M; Davidson S; Kanwar N; Fuligni F; Shlien A; Whitlock J; Villani A; Abla O
    Cancer Genet; 2020 Oct; 248-249():31-33. PubMed ID: 32992102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-omics analyses of MEN1 missense mutations identify disruption of menin-MLL and menin-JunD interactions as critical requirements for molecular pathogenicity.
    Dreijerink KMA; Ozyerli-Goknar E; Koidl S; van der Lelij EJ; van den Heuvel P; Kooijman JJ; Biniossek ML; Rodenburg KW; Nizamuddin S; Timmers HTM
    Epigenetics Chromatin; 2022 Aug; 15(1):29. PubMed ID: 35941657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Menin-MLL1 Interaction Small Molecule Inhibitors: A Potential Therapeutic Strategy for Leukemia and Cancers.
    Shi Q; Xu M; Kang Z; Zhang M; Luo Y
    Molecules; 2023 Mar; 28(7):. PubMed ID: 37049787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.
    Dzama MM; Steiner M; Rausch J; Sasca D; Schönfeld J; Kunz K; Taubert MC; McGeehan GM; Chen CW; Mupo A; Hähnel P; Theobald M; Kindler T; Koche RP; Vassiliou GS; Armstrong SA; Kühn MWM
    Blood; 2020 Nov; 136(21):2442-2456. PubMed ID: 32589720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Menin is necessary for long term maintenance of meningioma-1 driven leukemia.
    Libbrecht C; Xie HM; Kingsley MC; Haladyna JN; Riedel SS; Alikarami F; Lenard A; McGeehan GM; Ernst P; Bernt KM
    Leukemia; 2021 May; 35(5):1405-1417. PubMed ID: 33542482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
    Brzezinka K; Nevedomskaya E; Lesche R; Steckel M; Eheim AL; Haegebarth A; Stresemann C
    J Hematol Oncol; 2019 Jun; 12(1):66. PubMed ID: 31253180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitotic recombinatory evolution in acute leukemia.
    Papenhausen P; Kelly CA; Zhang Z; Penton A
    Cancer Genet; 2023 Jun; 274-275():33-40. PubMed ID: 36966725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of a novel type of KMT2A/EPS15 fusion transcript in FLT3 mutation-positive B-lymphoblastic leukemia with t(1;11)(p32;q23).
    Yamamoto K; Yakushijin K; Mizutani Y; Okuni-Watanabe M; Goto H; Higashime A; Miyata Y; Kitao A; Matsumoto H; Saegusa J; Matsuoka H; Minami H
    Cancer Genet; 2021 Jun; 254-255():92-97. PubMed ID: 33647817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Menin-MLL protein-protein interaction inhibitors: a patent review (2014-2021).
    Bai H; Zhang SQ; Lei H; Wang F; Ma M; Xin M
    Expert Opin Ther Pat; 2022 May; 32(5):507-522. PubMed ID: 35202550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML.
    Heikamp EB; Henrich JA; Perner F; Wong EM; Hatton C; Wen Y; Barwe SP; Gopalakrishnapillai A; Xu H; Uckelmann HJ; Takao S; Kazansky Y; Pikman Y; McGeehan GM; Kolb EA; Kentsis A; Armstrong SA
    Blood; 2022 Feb; 139(6):894-906. PubMed ID: 34582559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cryptic recurrent ACIN1-NUTM1 fusions in non-KMT2A-rearranged infant acute lymphoblastic leukemia.
    Pincez T; Landry JR; Roussy M; Jouan L; Bilodeau M; Laramée L; Couture F; Sinnett D; Gendron P; Hébert J; Oligny L; Rouette A; Tran TH; Wilhelm BT; Bittencourt H; Cellot S
    Genes Chromosomes Cancer; 2020 Feb; 59(2):125-130. PubMed ID: 31515871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Menin expression is regulated by transforming growth factor beta signaling in leukemia cells.
    Zhang H; Liu ZG; Hua XX
    Chin Med J (Engl); 2011 May; 124(10):1556-62. PubMed ID: 21740816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kmt2a cooperates with menin to suppress tumorigenesis in mouse pancreatic islets.
    Lin W; Francis JM; Li H; Gao X; Pedamallu CS; Ernst P; Meyerson M
    Cancer Biol Ther; 2016 Dec; 17(12):1274-1281. PubMed ID: 27801610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy-induced Deletion in 11q23 Leading to Fusion of
    Panagopoulos I; Andersen K; Eilert-Olsen M; Zeller B; Munthe-Kaas MC; Buechner J; Osnes LTN; Micci F; Heim S
    Cancer Genomics Proteomics; 2021; 18(1):67-81. PubMed ID: 33419897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.